首页> 外文期刊>Molecular pain >Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain
【24h】

Targeting macrophage and microglia activation with colony stimulating factor 1 receptor inhibitor is an effective strategy to treat injury-triggered neuropathic pain

机译:用集落刺激因子1受体抑制剂靶向巨噬细胞和小胶质细胞活化是治疗损伤触发的神经性疼痛的有效策略

获取原文
       

摘要

Neuropathic pain is a debilitating condition. The importance of neuroimmune interactions in neuropathic pain has been evidenced by the involvement of different immune cells in peripheral and central sensitization of pathological pain. Macrophages and microglia are the most abundant immune cells activated in injured nerves and spinal cord, respectively. Several lines of evidence showed that macrophage/microglia survival, activation, proliferation, and differentiation require the involvement of macrophage-colony stimulating factor. In this study, we investigated whether blocking macrophage-colony stimulating factor/colony stimulating factor 1 receptor signaling can be effective in relieving neuropathic pain. Partial sciatic nerve ligation was performed in mice to induce neuropathic pain behavior. Mice were orally treated with a selective colony stimulating factor 1 receptor inhibitor, PLX5622, daily in both preventive (two days prior to surgery until D14 post-partial sciatic nerve ligation) and reversal paradigms (D28–D33 post-partial sciatic nerve ligation). Animal neuropathic pain behavior was monitored using von Frey hairs and acetone application. Phenotype of macrophages in injured nerves was analyzed at D3 and D33 post-injury using flow cytometry analysis. The effect of PLX5622 on microglia activation in lumbar spinal cord was further examined by immunohistochemistry using Iba-1 antibody. Significant alleviation of both mechanical and cold allodynia was observed in PLX5622-treated animals, both in preventive and reversal paradigms. PLX5622 treatment reduced the total number of macrophages in injured nerves, it appears colony stimulating factor 1 receptor inhibition affected more specifically CD86+ (M1 like) macrophages. Consequently, the expression of various pro-inflammatory cytokines (TNF-α, IL-1β) was reduced. Microglia activation in dorsal horn of lumbar spinal cord following partial sciatic nerve ligation was significantly inhibited with PLX5622 treatment in both preventive and reversal paradigms. Macrophages in peripheral nerve and microglia in the spinal cord are required in the generation and maintenance of injury-associated neuropathic pain. Blocking macrophage-colony stimulating factor/colony stimulating factor 1 receptor signaling on these myeloid cells along the pain transmission pathway is an effective strategy to alleviate neuropathic pain.
机译:神经性疼痛是使人衰弱的病症。神经免疫性相互作用在神经性疼痛中的重要性已通过不同免疫细胞参与病理性疼痛的外周和中枢敏化而得到证实。巨噬细胞和小胶质细胞分别是在受损神经和脊髓中激活的最丰富的免疫细胞。几条证据表明,巨噬细胞/小胶质细胞的存活,激活,增殖和分化需要巨噬细胞集落刺激因子的参与。在这项研究中,我们调查了阻断巨噬细胞集落刺激因子/集落刺激因子1受体信号是否可以有效缓解神经性疼痛。在小鼠中进行部分坐骨神经结扎,以诱导神经性疼痛行为。预防性(手术前两天直至部分坐骨神经结扎后至D14)和逆转范式(部分坐骨神经结扎后D28–D33)均采用选择性集落刺激因子1受体抑制剂PLX5622进行口服口服治疗。使用冯·弗雷(von Frey)的头发和丙酮来监测动物的神经性疼痛行为。使用流式细胞仪分析受伤后第3天和第33天的巨噬细胞表型。使用Iba-1抗体通过免疫组织化学进一步检查了PLX5622对腰脊髓小胶质细胞活化的影响。在预防和逆转范例中,在用PLX5622处理的动物中均观察到了机械性和冷性异常性疼痛的明显缓解。 PLX5622处理减少了受伤神经中巨噬细胞的总数,似乎更特别地影响了CD86 + (M1样)巨噬细胞的集落刺激因子1受体抑制作用。因此,各种促炎细胞因子(TNF-α,IL-1β)的表达降低。在预防和逆转范例中,PLX5622治疗可显着抑制部分坐骨神经结扎后腰脊髓背角的小胶质细胞活化。损伤相关的神经性疼痛的产生和维持需要周围神经中的巨噬细胞和脊髓中的小胶质细胞。沿疼痛传递途径阻断这些髓样细胞上的巨噬细胞集落刺激因子/集落刺激因子1受体信号传导是缓解神经性疼痛的有效策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号